In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir

Diagn Microbiol Infect Dis. 1987 Mar;6(3):255-61. doi: 10.1016/0732-8893(87)90020-4.

Abstract

Fifty-four isolates of cytomegalovirus (CMV) from 25 immunocompromised patients with CMV infections were examined in a plaque reduction assay to determine in vitro susceptibilities to both acyclovir and ganciclovir. Isolates were approximately 25-fold more sensitive to ganciclovir than to acyclovir. The mean +/- SD ID50 for all isolates to acyclovir was 63.1 +/- 30.2 microM, (median, 52.3 microM; range, 16.7-146.4 microM). The mean ID50 for all isolates to ganciclovir was 2.50 +/- 1.27 microM, (median, 2.15 microM; range, 0.65-7.11 microM). Exposure to acyclovir or ganciclovir for periods of 2-5 wk did not alter the mean susceptibility of clinical isolates. However, one CMV strain isolated from a renal transplant patient after 14 days of acyclovir therapy displayed the lowest susceptibility of all strains tested (acyclovir 146.4 microM; ganciclovir 7.11 microM) and may represent selection of a resistant virus population.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acyclovir / analogs & derivatives*
  • Acyclovir / pharmacology*
  • Antiviral Agents / pharmacology*
  • Cytomegalovirus / drug effects*
  • Fibroblasts
  • Ganciclovir
  • Humans
  • Immune Tolerance
  • Viral Plaque Assay

Substances

  • Antiviral Agents
  • Ganciclovir
  • Acyclovir